About Cytosolic carboxypeptidase 1
Cytosolic carboxypeptidase 1 (AGTPBP1) is a protein
from Homo sapiens identified by UniProt accession
Q9UPW5, 1226 residues long.
MolForge cross-references it against 0 known binders and
489 disease associations.
Target properties
| Protein name | Cytosolic carboxypeptidase 1 |
|---|
| UniProt accession | Q9UPW5 |
|---|
| Gene | AGTPBP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1226 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (489)
Diseases linked to this target (Open Targets).
- neurodegeneration, childhood-onset, with cerebellar atrophy · score 0.77
- Global developmental delay · score 0.43
- Aplasia/Hypoplasia of the cerebellum · score 0.43
- pontocerebellar hypoplasia type 1 · score 0.37
- neurodegenerative disease · score 0.33
- neurodevelopmental disorder with cerebellar atrophy and with or without seizures · score 0.30
- motor peripheral neuropathy · score 0.26
- self reported educational attainment · score 0.23
- genetic disorder · score 0.19
- intelligence · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UPW5-F1 | alphafold | PREDICTED | 75.32 | — |
Amino-acid sequence (1226 residues)
MSKLKVIPEK SLTNNSRIVG LLAQLEKINA EPSESDTARY VTSKILHLAQ SQEKTRREMT AKGSTGMEIL LSTLENTKDL QTTLNILSIL VELVSAGGGR RVSFLVTKGG SQILLQLLMN ASKESPPHED LMVQIHSILA KIGPKDKKFG VKARINGALN ITLNLVKQNL QNHRLVLPCL QLLRVYSANS VNSVSLGKNG VVELMFKIIG PFSKKNSSLI KVALDTLAAL LKSKTNARRA VDRGYVQVLL TIYVDWHRHD NRHRNMLIRK GILQSLKSVT NIKLGRKAFI DANGMKILYN TSQECLAVRT LDPLVNTSSL IMRKCFPKNR LPLPTIKSSF HFQLPVIPVT GPVAQLYSLP PEVDDVVDES DDNDDIDVEA ENETENEDDL DQNFKNDDIE TDINKLKPQQ EPGRTIEDLK MYEHLFPELV DDFQDYDLIS KEPKPFVFEG KVRGPIVVPT AGEETSGNSG NLRKVVMKEN ISSKGDEGEK KSTFMDLAKE DIKDNDRTLQ QQPGDQNRTI SSVHGLNNDI VKALDRITLQ NIPSQTAPGF TAEMKKDCSL PLTVLTCAKA CPHMATCGNV LFEGRTVQLG KLCCTGVETE DDEDTESNSS VEQASVEVPD GPTLHDPDLY IEIVKNTKSV PEYSEVAYPD YFGHIPPPFK EPILERPYGV QRTKIAQDIE RLIHQSDIID RVVYDLDNPN YTIPEEGDIL KFNSKFESGN LRKVIQIRKN EYDLILNSDI NSNHYHQWFY FEVSGMRPGV AYRFNIINCE KSNSQFNYGM QPLMYSVQEA LNARPWWIRM GTDICYYKNH FSRSSVAAGG QKGKSYYTIT FTVNFPHKDD VCYFAYHYPY TYSTLQMHLQ KLESAHNPQQ IYFRKDVLCE TLSGNSCPLV TITAMPESNY YEHICHFRNR PYVFLSARVH PGETNASWVM KGTLEYLMSN NPTAQSLRES YIFKIVPMLN PDGVINGNHR CSLSGEDLNR QWQSPSPDLH PTIYHAKGLL QYLAAVKRLP LVYCDYHGHS RKKNVFMYGC SIKETVWHTN DNATSCDVVE DTGYRTLPKI LSHIAPAFCM SSCSFVVEKS KESTARVVVW REIGVQRSYT MESTLCGCDQ GKYKGLQIGT RELEEMGAKF CVGLLRLKRL TSPLEYNLPS SLLDFENDLI ESSCKVTSPT TYVLDEDEPR FLEEVDYSAE SNDELDIELA ENVGDYEPSA QEEVLSDSEL SRTYLP
Explore Cytosolic carboxypeptidase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets